Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treg and Tcon Immunotherapy in Allogeneic HCT
NCT01660607Phase 2Completed
- Sponsor
- Stanford University
- Start
- Feb 2012
- Primary completion
- Dec 2023
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of autologous regulatory T-lymphocytes in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), non-Hodgkin lymphoma (NHL), sponsored by Stanford University. Started Feb 2012; status: completed.
02
Drugs
autologous regulatory T-lymphocytes
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)myelodysplastic syndrome (MDS)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT01660607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01660607.